Key result
Statin treatment did not significantly reduce all-cause mortality, cardiovascular mortality, or the need for aortic valve surgery compared to placebo or no treatment in patients with non-rheumatic calcific aortic stenosis.
Why the study?
Does statin therapy improve outcomes and delay disease progression in patients with non-rheumatic calcific aortic stenosis?
Meta-Analysis (n=3,822)
Does statin therapy improve outcomes and delay disease progression in patients with non-rheumatic calcific aortic stenosis?
Statin therapy does not improve hard clinical outcomes or consistently reduce disease progression in non-rheumatic calcific aortic stenosis.
Answers are grounded in this paper and cite their sources.
Statin therapy should not be used to improve outcomes in non-rheumatic calcific aortic stenosis; confirms lack of benefit on mortality and valve surgery.
CONTEXT: It is not known whether statin treatment improves clinical outcomes and reduces aortic stenosis progression in non-rheumatic calcific aortic stenosis. OBJECTIVE: A meta-analysis of studies was performed comparing statin therapy with placebo or no treatment on outcomes and on aortic stenosis progression echocardiographic parameters. DATA SOURCES: The authors searched Medline and Pubmed up to January 2010. DATA EXTRACTION: Two independent reviewers independently abstracted information on study design (prospective vs retrospective or randomised vs non-randomised), study and participant characteristics. Fixed and random effects models were used. A-priori subanalyses assessed the effect of statins on low-quality (retrospective or non-randomised) and on high-quality (prospective or randomised) studies separately. RESULTS: Meta-analysis identified 10 studies with a total of 3822 participants (2214 non-statin-treated and 1608 statin-treated); five studies were classified as prospective and five as retrospective; concerning randomisation, three trials were randomised whereas seven were not. No significant differences were found in all-cause mortality, cardiovascular mortality or in the need for aortic valve surgery. Lower-quality (retrospective or non-randomised) studies showed that, in statin-treated patients, the annual increase in peak aortic jet velocity and the annual decrease in aortic valve area were lower, but this was not confirmed by the analysis in high-quality (prospective or randomised) studies. Statins did not significantly affect the progression over time of peak and mean aortic gradient. CONCLUSIONS: Currently available data do not support the use of statins to improve outcomes and to reduce disease progression in non-rheumatic calcific aortic valve stenosis.
No takes yet. Share an insight, caveat, or question.
Parolari et al. (2011) conducted a meta-analysis in non-rheumatic calcific aortic stenosis (n=3,822). Statins vs. Placebo or no statin treatment was evaluated on All-cause mortality (OR 0.98, 95% CI 0.74-1.30, p=0.91). Statin treatment did not significantly reduce all-cause mortality, cardiovascular mortality, or the need for aortic valve surgery compared to placebo or no treatment in patients with non-rheumatic calcific aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: